SEPTInvestingStart Free

FATE SCHEDULE 13D/A: SEC filing

Redmile Group and affiliated entities

Filed with the SEC on · accession 0000905148-26-004718

FATE filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 9, 2026. Redmile Group and affiliated entities filed an amended Schedule 13D adding Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% of Fate Therapeutics solely due to a decrease in the issuer's outstanding share count. The stock moved +5.7% by the first close after the filing.

Summary of the filing

Redmile Group and affiliated entities filed an amended Schedule 13D adding Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% of Fate Therapeutics solely due to a decrease in the issuer's outstanding share count. No transactions were made by the reporting persons.

For details, click here →

Key details

Shares beneficially owned by Redmile Group, LLC (14.99% of outstanding)$19.2M
Shares beneficially owned by RedCo II Offshore SPV LLC (8.12% of outstanding)$10.1M
Shares beneficially owned by Redmile Capital Offshore II Master Fund, Ltd. (5.03% of outstanding)$6.4M
IssuerFate Therapeutics, Inc.
Reporting person / investment managerRedmile Group, LLC
Reporting person / private investment fundRedCo II Offshore SPV LLC
Reporting person / private investment fundRedmile Capital Offshore II Master Fund, Ltd.
Managing member of redmile group, llcJeremy C. Green

How FATE stock reacted

Close before

$1.83

Nov 6, 2026

First close after

+5.72%

$1.94

5 trading days

—

Since filing

-3.54%

$1.77

✦ Ask GOAX AI about this filing — what it means for FATE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for FATE?

Click here

Frequently asked questions

What did FATE file with the SEC on Nov 9, 2026?

FATE filed a SCHEDULE 13D/A (SEC filing). Redmile Group and affiliated entities filed an amended Schedule 13D adding Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% of Fate Therapeutics solely due to a decrease in the issuer's outstanding share count. No transactions were made by the reporting persons.

How do I read a SCHEDULE 13D/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).

How did FATE stock react to this filing?

FATE closed at $1.83 before the filing and $1.94 on Nov 9, 2026 (+5.72%).

Other FATE SEC filings

Get alerts when FATE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
FATE overviewFATE analysisFATE newsLatest SEC filings